Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Nonresponders

Clin Exp Allergy. 2024 Sep;54(9):694-696. doi: 10.1111/cea.14518. Epub 2024 Jul 24.
No abstract available

Keywords: atopic dermatitis; clinical immunology; dermatology; epidemiology; pediatrics.

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Child
  • Child, Preschool
  • Dermatitis, Atopic* / drug therapy
  • Drug Resistance
  • Female
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Male
  • Treatment Outcome

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized
  • upadacitinib
  • Heterocyclic Compounds, 3-Ring